Good morning. Fortune senior writer Maria Aspan here.
We will do anything to survive outside of bankruptcy. CEO Saundra Pelletier has spent the past year watching her pharma company, Evofem Biosciences, slowly slip to the brink of failure. She also spent the past two months talking to me about her companys struggles, offering Fortunes readers a rare window into how top executives manage throughand try to avertthe ultimate business disaster.
Evofems shares have been delisted from the Nasdaq, and its sales arent growing fast enough to overcome its losses (or its debt load). Last month, the San Diego company parted ways with most of Pelletiers remaining staff, including members of her C-Suite: her CFO resigned, her chief commercial officer was laid off, and her 35 remaining employees took salary cuts of 20%. (Pelletiers own salary was slashed by 40%, to $520,000.)
Still, Pelletier isnt giving up yet. Evofems latest round of blood-letting will cut about $4.3 million in expenses, buying her company another few months of operating budget, while she keeps searching for a buyer or investor or another savior.
We are on life support, she says. But theres nothing I would not do for this company to succeed.
There are many reasons for Evofems current predicament, including some of Pelletiers own making, as I report in a new profile and investigation for Fortune. The company, which makes a prescription contraceptive gel called Phexxi, has survived expensive regulatory limbo; product setbacks; and even some personal tragedies, including plane crashes and cancer diagnoses.
But the biggest financial challenges facing Evofemand all the entrepreneurs and executives trying to innovate in its crucial marketinvolve our broken health care system. Its part of a much bigger story about how reluctant big drugmakers are to invest in womens healthand about how much power big insurance companies wield over small pharma companies like Evofem, to block their innovation and growth.
Weve never clawed our way back in the public market because now weve got to face the insurance companies, says Al Altomari, the CEO of Agile Therapeutics, another small company that launched a new contraceptive called Twirla in 2020and quickly ran into some of the same financial obstacles as Evofem.
Check out the full story, which follows Pelletiers tireless efforts to save her companywhile diving into the systemic, industry-wide problems facing Evofem, Agile, and the 73 million U.S. women who are their prospective customers.
Maria Aspan
This email address is being protected from spambots. You need JavaScript enabled to view it.
@mariaaspan
Upcoming event: The next Fortune Emerging CFO virtual event, Addressing the Talent Gap with Advanced Technologies, presented in partnership with Workday (a CFO Daily sponsor), will take place from 11 a.m.-12 p.m. EST on April 12. Matt Heimer, executive editor of features at Fortune, and CFO Dailys Sheryl Estrada will be joined by TELUS International CFO Vanessa Kanu; Alight Solutions CFO Katie Rooney; and Tom Davenport, author, All-in on A.I., Presidents Distinguished Professor at Babson College, fellow at MIT Initiative for the Digital Economy, and visiting professor at Saïd Business School, University of Oxford. Click here to learn more and register.
Big deal
More Americans worry about inflation and the economy than any of the other key problems facing the U.S., according to Gallups annual survey. Six in 10 Americans surveyed expressed a great deal of concern about these issues. This year, more are also worried about the affordability of health care (54% in 2023 vs. 49% in 2022), and federal spending and the budget deficit (52% vs. 48%), according to the report.
Going deeper
"Finding the Model That Captures Investment Risks, but Not Mispricing of Assets," a report in Wharton's Business Journal, shows fund managers a way to isolate the mispricing of securities to weigh the role of risks. Robert F. Stambaugh, the Miller Anderson & Sherrerd professor of finance at Wharton, is a co-author of a research paper that tests the ability of five prominent models to predict future returns by evaluating only risks, assuming that there is no mispricing, according to the report.
Leaderboard
Janet Yang, EVP and CFO at W&T Offshore, Inc. (NYSE: WTI), an independent oil and natural gas producer, announced she will leave the company on May 11, following the release of the first quarter earnings and the filing of the 10-Q. Yang disclosed that, for family reasons, she and her family will be relocating to another city. Trey Hartman, VP and chief accounting officer, will serve as interim CFO. A formal search for a permanent CFO will be initiated shortly, according to the company.
Conor McCarthy was named CFO at MariaDB plc (NYSE: MRDB), a generation cloud database company, effective April 10. McCarthy has over 30 years of experience leading finance organizations. Previously, he was CFO at Ideanomics, a cleantech company. Before Ideanomics, McCarthy was CFO at OS33 and CFO at Intent Media Inc. He also spent nine years at wholesale brokerage firm GFI Group Inc., now part of BGC Partners, where he was CFO-Americas.
Overheard
The bond market has gone berserk. For once, Im on the side of equity markets. I dont see a recession coming.
Dominique Dwor-Frecaut, a senior market strategist at the research firm Macro Hive Ltd., told Bloomberg. Dwor-Frecaut previously worked in the New York Feds markets group.
This is the web version of CFO Daily, a newsletter on the trends and individuals shaping corporate finance. Sign up to get CFO Daily delivered free to your inbox.
